Search
AnaptysBio Inc
ANABAdd to Watchlist
53.360USD
-1.680-3.05%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.58BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of AnaptysBio Inc is 8.73, ranking 70 out of 385 in the Biotechnology & Medical Research industry. The average price target is 62.50, with a high of 100.00 and a low of 20.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
88.800
Target Price
+66.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
AnaptysBio Inc
ANAB
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is AnaptysBio Inc's expected revenue for the next quarter?
AnaptysBio Inc's expected revenue is 30.66M.
What is AnaptysBio Inc's price target?
Analysts forecast that AnaptysBio Inc's price target is USD 62.50, with the highest forecast at USD 100.00 and the lowest forecast at USD 20.00.
How have AnaptysBio IncANAB's recent earnings per share performed?
The market expectation was USD -1.84, while AnaptysBio IncANAB's earnings per share (EPS) for the previous quarter was USD -0.46. EPS for the next quarter is expected at USD -0.07.
What is the analyst rating for AnaptysBio Inc?
Based on the ratings of AnaptysBio Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.